Gilead

For more than 35 years, Gilead has led the evolution of HIV treatment and prevention. Our continued focus on advancing a diverse, next‑generation pipeline reflects our unwavering commitment to scientific innovation. We also understand that ending the HIV epidemic requires more than medicines—it demands sustained leadership, inclusive science, and global collaboration. At Gilead, we pair breakthrough innovation with action to expand access and dismantle inequities, partnering with communities most affected by HIV to drive durable progress and work toward a world without HIV.

MSD

MSD’s Commitment to HIV

For more than 35 years, MSD has been committed to scientific research and discovery in HIV leading to scientific breakthroughs that have helped change HIV treatment. Our work has helped pioneer the development of new options across multiple drug classes to help those impacted by HIV. Today, we are developing a series of antiviral options designed to help people manage their HIV and to help prevent HIV, with the goal of reducing the growing burden of infection worldwide. We want to ensure people are not defined by HIV, and our work focuses on transformational innovations, collaborations with others in the global HIV community, and access initiatives aimed at helping to end the HIV epidemic for everyone.

ViiV

We are ViiV Healthcare: the only global pharmaceutical company 100% dedicated to preventing, treating and curing HIV. At ViiV Healthcare we do things differently. From our unique origins to our innovative medicines, we push the boundaries of what people think is possible in HIV innovation and care.

https://viivhealthcare.com/